Loading...

OncoTherapy Science

DB:30O
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
30O
DB
¥19B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
30O Share Price and Events
7 Day Returns
-1.3%
DB:30O
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-40.8%
DB:30O
-5.6%
DE Biotechs
-4.5%
DE Market
30O Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OncoTherapy Science (30O) -1.3% -8.7% -14.4% -40.8% -63.4% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 30O underperformed the Biotechs industry which returned -5.6% over the past year.
  • 30O underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
30O
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for OncoTherapy Science's competitors could be found in our database.

Value

 Is OncoTherapy Science undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OncoTherapy Science. This is due to cash flow or dividend data being unavailable. The share price is €0.959.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OncoTherapy Science's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OncoTherapy Science's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:30O PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-17.68
TSE:4564 Share Price ** TSE (2019-04-25) in JPY ¥123
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OncoTherapy Science.

DB:30O PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4564 Share Price ÷ EPS (both in JPY)

= 123 ÷ -17.68

-6.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoTherapy Science is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OncoTherapy Science is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OncoTherapy Science's expected growth come at a high price?
Raw Data
DB:30O PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OncoTherapy Science, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OncoTherapy Science's assets?
Raw Data
DB:30O PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥36.75
TSE:4564 Share Price * TSE (2019-04-25) in JPY ¥123
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:30O PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4564 Share Price ÷ Book Value per Share (both in JPY)

= 123 ÷ 36.75

3.35x

* Primary Listing of OncoTherapy Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoTherapy Science is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OncoTherapy Science's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OncoTherapy Science has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OncoTherapy Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncoTherapy Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OncoTherapy Science expected to grow at an attractive rate?
  • Unable to compare OncoTherapy Science's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare OncoTherapy Science's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare OncoTherapy Science's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:30O Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:30O Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:30O Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:30O Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 255 -2,599
2018-09-30 34 -2,870 -3,026
2018-06-30 24 -2,930
2018-03-31 211 -3,035 -2,851
2017-12-31 255 -2,949
2017-09-30 453 -2,839 -2,872
2017-06-30 486 -2,806
2017-03-31 286 -2,988 -3,002
2016-12-31 290 -2,864
2016-09-30 92 -2,970 -2,951
2016-06-30 60 -3,012
2016-03-31 266 -2,898 -2,788

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if OncoTherapy Science is high growth as no earnings estimate data is available.
  • Unable to determine if OncoTherapy Science is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:30O Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from OncoTherapy Science Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:30O Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:30O Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -17.68
2018-09-30 -20.58
2018-06-30 -19.93
2018-03-31 -19.39
2017-12-31 -20.06
2017-09-30 -19.53
2017-06-30 -19.08
2017-03-31 -20.42
2016-12-31 -19.48
2016-09-30 -20.07
2016-06-30 -20.49
2016-03-31 -18.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OncoTherapy Science will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine OncoTherapy Science's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. OncoTherapy Science's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. OncoTherapy Science's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess OncoTherapy Science's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OncoTherapy Science has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OncoTherapy Science performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OncoTherapy Science's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OncoTherapy Science does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OncoTherapy Science's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OncoTherapy Science's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OncoTherapy Science's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OncoTherapy Science Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:30O Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 255.00 -2,599.00 268.00
2018-09-30 34.00 -3,026.00 266.00
2018-06-30 24.00 -2,930.00 249.00
2018-03-31 211.00 -2,851.00 251.00
2017-12-31 255.00 -2,949.00 192.00
2017-09-30 453.00 -2,872.00 214.00
2017-06-30 486.00 -2,806.00 234.00
2017-03-31 286.00 -3,002.00 262.00
2016-12-31 290.00 -2,864.00 278.00
2016-09-30 92.00 -2,951.00 285.00
2016-06-30 60.00 -3,012.00 295.00
2016-03-31 266.00 -2,788.00 296.00
2015-12-31 581.00 -2,464.00 319.00
2015-09-30 626.00 -1,921.00 302.00
2015-06-30 671.00 -1,706.00 296.00
2015-03-31 769.00 -1,334.00 282.00
2014-12-31 651.00 -1,769.00 225.00
2014-09-30 1,035.00 -2,409.00 229.00
2014-06-30 1,110.00 -2,793.00 250.00
2014-03-31 1,017.00 -3,676.00 235.00
2013-12-31 2,303.00 -2,425.00 293.00
2013-09-30 2,479.00 -1,998.00 281.00
2013-06-30 3,134.00 -1,409.00 235.00
2013-03-31 3,277.00 -1,103.00 231.00
2012-12-31 6,504.00 1,322.00 249.00
2012-09-30 6,376.00 1,114.00 256.00
2012-06-30 6,240.00 994.00 260.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OncoTherapy Science has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OncoTherapy Science has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OncoTherapy Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OncoTherapy Science's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OncoTherapy Science has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OncoTherapy Science's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OncoTherapy Science's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OncoTherapy Science is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OncoTherapy Science's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OncoTherapy Science's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OncoTherapy Science has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OncoTherapy Science Company Filings, last reported 3 months ago.

DB:30O Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5,424.00 0.00 4,877.00
2018-09-30 5,842.00 0.00 5,339.00
2018-06-30 6,860.00 0.00 5,894.00
2018-03-31 7,578.00 0.00 6,740.00
2017-12-31 8,337.00 0.00 7,688.00
2017-09-30 8,829.00 0.00 8,686.00
2017-06-30 9,514.00 0.00 9,183.00
2017-03-31 10,104.00 0.00 10,072.00
2016-12-31 10,907.00 0.00 10,884.00
2016-09-30 11,613.00 0.00 11,415.00
2016-06-30 12,345.00 0.00 12,114.00
2016-03-31 13,114.00 0.00 13,070.00
2015-12-31 13,814.00 0.00 13,687.00
2015-09-30 14,606.00 0.00 14,405.00
2015-06-30 15,401.00 0.00 15,428.00
2015-03-31 16,064.00 0.00 16,071.00
2014-12-31 16,401.00 0.00 16,471.00
2014-09-30 16,912.00 0.00 16,926.00
2014-06-30 17,496.00 0.00 17,302.00
2014-03-31 17,781.00 0.00 17,825.00
2013-12-31 18,547.00 0.00 18,538.00
2013-09-30 19,362.00 0.00 19,014.00
2013-06-30 9,504.00 0.00 8,938.00
2013-03-31 10,357.00 0.00 8,497.00
2012-12-31 9,847.00 0.00 8,962.00
2012-09-30 10,265.00 0.00 9,676.00
2012-06-30 10,602.00 0.00 10,159.00
  • OncoTherapy Science has no debt.
  • OncoTherapy Science has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OncoTherapy Science has sufficient cash runway for 1.5 years based on current free cash flow.
  • OncoTherapy Science has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 5.2% each year.
X
Financial health checks
We assess OncoTherapy Science's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OncoTherapy Science has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OncoTherapy Science's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OncoTherapy Science dividends.
If you bought €2,000 of OncoTherapy Science shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OncoTherapy Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OncoTherapy Science's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:30O Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:30O Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OncoTherapy Science has not reported any payouts.
  • Unable to verify if OncoTherapy Science's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OncoTherapy Science's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OncoTherapy Science has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OncoTherapy Science's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OncoTherapy Science afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OncoTherapy Science has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OncoTherapy Science's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kyoko Fujiya
TENURE AS CEO 0.3 years
CEO Bio

Kyoko Fujiya serves as a President & CEO at OncoTherapy Science, Inc. since January 2019.

CEO Compensation
  • Insufficient data for Kyoko to compare compensation growth.
  • Insufficient data for Kyoko to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Kyoko Fujiya

TITLE
President & CEO
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the OncoTherapy Science board of directors in years:

4.6
Average Tenure
57
Average Age
  • The tenure for the OncoTherapy Science board of directors is about average.
Board of Directors

Yuichi Komine

TITLE
External Director
AGE
47
TENURE
4.6 yrs

Toyomasa Katagiri

TITLE
External Director
AGE
53
TENURE
8.8 yrs

Tomoaki Fujioka

TITLE
External Director
AGE
70
TENURE
4.6 yrs

Jae Park

TITLE
Director
TENURE
0.8 yrs

Miyako Takagi

TITLE
External Auditor
AGE
66
TENURE
14.8 yrs

Shuichi Nakatsuru

TITLE
Full-Time Auditor
AGE
61
TENURE
10.8 yrs

Teruhisa Tajima

TITLE
External Auditor
AGE
47
TENURE
4.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess OncoTherapy Science's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OncoTherapy Science has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company’s clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for soft tissue synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer’s disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

Details
Name: OncoTherapy Science, Inc.
30O
Exchange: DB
Founded: 2001
¥150,115,640
151,557,400
Website: http://www.oncotherapy.co.jp
Address: OncoTherapy Science, Inc.
Building D,
11th Floor, Kanagawa Science Park,
Kawasaki,
Kanagawa, 213-0012,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4564 Common Stock The Tokyo Stock Exchange JP JPY 08. Dec 2003
DB 30O Common Stock Deutsche Boerse AG DE EUR 08. Dec 2003
Number of employees
Current staff
Staff numbers
56
OncoTherapy Science employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:33
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2018/05/11
Last earnings filing: 2019/02/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.